Tags

Type your tag names separated by a space and hit enter

Irritable bowel syndrome: focus on otilonium bromide.

Abstract

Irritable bowel syndrome is a prevalent and chronic disorder, characterized by recurrent abdominal pain/discomfort, bloating and altered bowel habits. This condition affects an estimated 10-15% of the population worldwide and impacts heavily on a patient's daily life and ability to work, as well as healthcare resource utilization. Drug therapy aimed at correcting the primary symptoms of diarrhea/constipation/bloating may have little effect on abdominal pain, which results from visceral hypersensitivity. Smooth muscle relaxants or antispasmodics decrease the tone and contractility of intestinal smooth muscle, effectively managing abdominal pain. Otilonium bromide has been widely used worldwide and has been found to be safe and well tolerated, and superior to placebo for the reduction of symptoms and the prevention of symptom relapse in patients with irritable bowel syndrome.

Authors+Show Affiliations

Department of Gastroenterology, University of Leuven, Leuven, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24417261

Citation

Boeckxstaens, Guy, et al. "Irritable Bowel Syndrome: Focus On Otilonium Bromide." Expert Review of Gastroenterology & Hepatology, vol. 8, no. 2, 2014, pp. 131-7.
Boeckxstaens G, Clavé P, Corazziari ES, et al. Irritable bowel syndrome: focus on otilonium bromide. Expert Rev Gastroenterol Hepatol. 2014;8(2):131-7.
Boeckxstaens, G., Clavé, P., Corazziari, E. S., & Tack, J. (2014). Irritable bowel syndrome: focus on otilonium bromide. Expert Review of Gastroenterology & Hepatology, 8(2), pp. 131-7. doi:10.1586/17474124.2014.869477.
Boeckxstaens G, et al. Irritable Bowel Syndrome: Focus On Otilonium Bromide. Expert Rev Gastroenterol Hepatol. 2014;8(2):131-7. PubMed PMID: 24417261.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Irritable bowel syndrome: focus on otilonium bromide. AU - Boeckxstaens,Guy, AU - Clavé,Pere, AU - Corazziari,Enrico S, AU - Tack,Jan, PY - 2014/1/15/entrez PY - 2014/1/15/pubmed PY - 2014/9/23/medline SP - 131 EP - 7 JF - Expert review of gastroenterology & hepatology JO - Expert Rev Gastroenterol Hepatol VL - 8 IS - 2 N2 - Irritable bowel syndrome is a prevalent and chronic disorder, characterized by recurrent abdominal pain/discomfort, bloating and altered bowel habits. This condition affects an estimated 10-15% of the population worldwide and impacts heavily on a patient's daily life and ability to work, as well as healthcare resource utilization. Drug therapy aimed at correcting the primary symptoms of diarrhea/constipation/bloating may have little effect on abdominal pain, which results from visceral hypersensitivity. Smooth muscle relaxants or antispasmodics decrease the tone and contractility of intestinal smooth muscle, effectively managing abdominal pain. Otilonium bromide has been widely used worldwide and has been found to be safe and well tolerated, and superior to placebo for the reduction of symptoms and the prevention of symptom relapse in patients with irritable bowel syndrome. SN - 1747-4132 UR - https://www.unboundmedicine.com/medline/citation/24417261/Irritable_bowel_syndrome:_focus_on_otilonium_bromide_ L2 - http://www.tandfonline.com/doi/full/10.1586/17474124.2014.869477 DB - PRIME DP - Unbound Medicine ER -